<DOC>
	<DOCNO>NCT00294866</DOCNO>
	<brief_summary>Studies show patient ESRD hemodialysis high level inflammatory marker may contribute high rate cardiovascular disease mortality see patient . Vitamin D use dialysis patient show survival benefit , paricalcitol advantage calcitriol . Since evidence involvement vitamin D receptor inflammation , study design look effect paricalcitol marker inflammation hemodialysis patient .</brief_summary>
	<brief_title>Effect Paricalcitol Markers Inflammation Hemodialysis Patients</brief_title>
	<detailed_description>Patients ESRD high incidence acute phase inflammation . Studies show C-reactive Protein ( CRP ) interleukin-6 ( IL-6 ) excellent biomarkers inflammation , high level predictive cardiovascular morbidity mortality population . Both uremia dialysis process contribute inflammatory state . It hypothesis paricalcitol therapy decrease biomarkers inflammation may implications future study morbidity mortality population .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>1 . CKD receive hemodialysis great equal 3 month 2 . Age great equal 18 year 3 . Medically stable 4 . AVF PTFE dialysis access 5 . No acute inflammatory disease within 4 week prior study 6 . On average dose 3 7 mcg paricalcitol three time per week 4 week prior study 7 . Two consecutive iPTH 150400 ( biPTH 75 200 ) =/ 30 % one week apart 8 . Ca &lt; 10.2 mg/dL ; PO4 &lt; 7.0 9 . Kt/V great equal 1.2 10 . On interventional drugs/devices past 30 day 1 . Currently receive dialysis use venous catheter access 2 . Currently receive high dose immunosuppressive therapy ( great equal 10 mg prednisone ) 3 . Pregnancy 4 . Hospitalization within last 4 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>End Stage Renal Disease</keyword>
	<keyword>Inflammation</keyword>
</DOC>